Here are four things to know:
1. In the double-blinded, randomized controlled trial, Dr. Trale injected either a placebo saline solution or a solution containing stem cells as the surgical team closed the wound. The trial is intended to regenerate muscle tissue for a quicker recovery period.
2. Pluristem develops placenta-based cell therapy products. In April, Pluristem received FDA clearance for a phase 3 study of its PLX-PAD cell therapy for the treatment of muscle injury after surgery.
PLX is an abbreviation for “placental expanded,” while PAD refers to placental-derived adherent or mesenchymal stromal cells.
3. The 83-year-old patient fell and broke the femoral neck of his hip. This fracture type has up to a 36 percent mortality rate, with annual U.S. treatment costs estimated to be between $10 billion and $15 billion.
4. Dr. Trale specializes in total knee and hip replacements and shoulder surgery.
More articles on biologics:
Regenexx makes new partnership to reduce musculoskeletal surgery costs
10 leading players in the global orthopedic biomaterials market
Bioengineered ACL implant startup raises $22.5M: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
